+5 | The top 5 medtech stories for March 22, 2017

This article was originally published here


Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.

Get this in your inbox everyday by subscribing to our newsletters.

5. Japan clears Novocure’s 2nd gen Optune device news

Novocure said today it won approval from the Japanese Ministry of Health, Labour and Welfare for its 2nd-gen Optune device.

The Optune is a mobile device that delivers low-intensity, intermediate frequency, alternating electric fields, referred to as “tumor treating fields” to inhibit cancer cell replication and cause cancer cell death, the St. Helier, N.J.-based company said. Read more

4. Medtronic plans $2B debt flotation news

Medtronic today announced a series of upcoming offerings, looking to bring in approximately $2 billion.

The Fridley, Minn.-based company announced 2 offerings to be held through its subsidiary Medtronic Global Holdings, or Medtronic Luxco, looking to bring in $1 billion in 1.7% senior notes due 2019 and $850 million in 3.35% senior notes due 2027. Read more

3. Hologic closes $1.7B Cynosure buy news

Hologic said today that it closed its $1.65 billion acquisition of Cynosure Inc. and its portfolio of medical aesthetic products and devices.

Marlborough, Mass.-based Hologic paid $66 per share for a total of 17 million shares of Class A stock, representing approximately 70.6% of the company’s outstanding shares. Read more

2. FDA warns on lymphoma risk associated with breast implants news

The FDA this month warned of an association between breast implants and the development anapestic large cell lymphoma.

The federal watchdog warned that the rare T-cell lymphoma can develop following implants, based on data the agency, and other health and regulatory bodies worldwide, have been collecting since 2011. Read more

1. Medtronic wins FDA nod for CoreValve Evolut Pro news

Medtronic said today it won FDA approval for its CoreValve Evolut Pro transcatheter arortic heart valve replacement designed for treating severe aortic stensosis.

The newly cleared, next-gen CoreValve Evolut Pro features an outer wrap to add surface area contact between the valve and the native aortic annulus to increase valve sealing performance, Fridley, Minn.-based Medtronic said. Read more

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply